Helicase-primase inhibitors from Medshine Discovery Inc. (WO2018/127207 and WO2020/007355) for the treatment of herpes simplex virus infections – structure proposal for Phaeno Therapeutics drug candidate HN0037
Sign Up to like & getrecommendations! Published in 2022 at "Expert Opinion on Therapeutic Patents"
DOI: 10.1080/13543776.2022.2113873
Abstract: ABSTRACT Helicase-primase is an interesting target for small-molecule therapy of herpes simplex virus (HSV) infections. With amenamevir already approved for varicella-zoster virus and with pritelivir’s granted breakthrough therapy designation for the treatment of acyclovir-resistant HSV… read more here.
Keywords: simplex virus; drug candidate; phaeno therapeutics; helicase primase ... See more keywords
Amenamevir, a Helicase-Primase Inhibitor, for the Optimal Treatment of Herpes Zoster
Sign Up to like & getrecommendations! Published in 2021 at "Viruses"
DOI: 10.3390/v13081547
Abstract: Acyclovir, valacyclovir, and famciclovir are used for the treatment of herpes simplex virus (HSV) and varicella-zoster virus (VZV) infections. Helicase-primase inhibitors (HPIs) inhibit replication fork progression that separates double DNA strands into two single strands… read more here.
Keywords: treatment herpes; herpes zoster; helicase primase; amenamevir helicase ... See more keywords